THE ONLY ONCE-DAILY ORAL PARP INHIBITOR WITH PROVEN EFFICACY REGARDLESS OF BRCA STATUS1-4

ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3

See the NOVA Trial Data

The primary endpoint of the pivotal trial (NOVA), was progression-free survival (PFS) from time of randomization to time of disease progression or death. At the time of the PFS analysis, limited overall survival data were available, with 17% of survival events occurring in the study.1,4,5

Median PFS in the NOVA clinical trial:

Median progression-free survival was 21 months in gBRCAmut cohort of patients on ZEJULA® vs. 5.5 months in patients on placebo
Median progression-free survival was 9.3 months in non-gBRCAmut cohort of patients on ZEJULA® vs. 3.9 months in patients on placebo
Median progression-free survival was 21 months in gBRCAmut cohort of patients on ZEJULA® vs. 5.5 months in patients on placebo
Median progression-free survival was 9.3 months in non-gBRCAmut cohort of patients on ZEJULA® vs. 3.9 months in patients on placebo

BRCA, breast cancer susceptibility gene; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.

Sign-up for more information

REQUEST MORE INFORMATION

Sign-up to request a rep

Sign-up
Efficacy data

EFFICACY DATA

View PFS by cohort, including non-gBRCAmut

View Efficacy
Safety data

SAFETY DATA

Learn about the safety and tolerability of ZEJULA

See Safety
Back to Top